How a Sequence Gets Built, One Residue at a Time

The hardest impurity to remove from a synthetic peptide is the one that is almost the peptide: a chain identical to the target except that a single residue never went on. It elutes close to the main peak because it is chemically close to the main peak, and the reason it exists at all is written into the manufacturing method. Nearly all research peptide is assembled by solid-phase peptide synthesis, and that method’s characteristic failure mode is exactly this.

An arithmetic that punishes long sequences

Residues are added one at a time, and no addition works on every chain in the vessel. Suppose each one succeeds 99 percent of the time – a respectable figure. After ten residues the share of chains still carrying the intended sequence has fallen to roughly 90 percent. After thirty it is around 74 percent. Compounding does the damage, and it is the principal reason that making long peptides well is both difficult and costly.

The chains that miss a coupling are not removed from the reaction. They travel on through every subsequent round, one residue short, and emerge at the end as deletion sequences: the impurity class that most resembles the product and is consequently the most stubborn to separate from it. What the various classes look like is set out in deletion, truncation and oxidation impurities.

What adding one residue actually involves

The chain is built while tethered to an insoluble resin bead, and that tether is the entire point of the technique. Since the growing peptide cannot dissolve, surplus reagents and reaction debris are removed by filtering and rinsing instead of by isolating an intermediate. Purification between steps collapses into a wash.

Assembly proceeds from the C-terminal end toward the N-terminal end, reversing the direction biology uses. Residue one is fixed to the bead; every residue after it is joined to the free amino group left exposed by its predecessor.

Four operations, repeated, install each one. Under Fmoc chemistry, which is standard for research-grade material, a base – piperidine in most protocols – first strips the Fmoc group masking the chain’s N-terminal amine, uncovering it. A rinse then clears out the base and the protecting-group fragments it released. Next comes the coupling itself: the incoming amino acid, carrying its own Fmoc group and side-chain protection, is activated and forms an amide bond to the exposed amine. A second rinse carries off whatever activated amino acid went unused, leaving the bead ready for the following deprotection. One pass per residue, so a twenty-nine residue sequence such as GHRH(1-29) requires twenty-nine passes. That sequence is discussed in sermorelin as the reference GHRH analog.

Acetylation as damage limitation

Because deletion sequences are the problem, many protocols insert a capping operation immediately after coupling. Any chain that failed to react gets acetylated, which shuts its N-terminus permanently. Such chains are frozen where they stand rather than continuing to accumulate residues around a gap.

Note what this does and does not buy. The quantity of correct product is unchanged, since a capped chain was already lost. What improves is the downstream separation. Terminate a failed chain early and it ends up short, markedly less like the target in hydrophobicity, and easy to resolve chromatographically. Allow it to run to completion one residue light and it is not.

Off the bead and into the vial

When the last residue is in place, strong acid – trifluoroacetic acid plus scavengers, as a rule – performs two jobs at once, releasing the peptide from its support and removing the side-chain protecting groups. Scavengers are present to mop up the reactive fragments generated during that release, which would otherwise attack vulnerable residues.

Preparative reversed-phase HPLC then cleans up the crude material, and the purified fraction is freeze-dried. Between the acid at cleavage and the acid in the preparative mobile phase, it follows that a great deal of synthetic peptide arrives as a trifluoroacetate salt. What that implies for the mass you weigh out is covered in TFA and acetate counter-ions, and the drying stage itself in lyophilization.

All material is supplied for laboratory research use only. It is not a drug, not a supplement, and not for use in humans or animals.